SAGIMET BIOSCIENCES INC.

Analyst Reco. Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
4.62 ^USD	+5.48%		+4.05%	-14.76%

May. 16	Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	MT
May. 15	Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	May. 16	MT
HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target	May. 02	MT
Goldman Sachs Adjusts Sagimet Biosciences' Price Target to $27 From $37, Maintains Buy Rating	Mar. 26	MT
Leerink Partners Initiates Sagimet Biosciences With Outperform Rating, $26 Price Target	Mar. 25	MT
JMP Securities Adjusts Price Target on Sagimet Biosciences to $46 From $47, Maintains Market Outperform Rating	Feb. 07	MT
Goldman Sachs Raises Price Target on Sagimet Biosciences to $37 From $30, Keeps Buy Rating	Jan. 23	MT
JMP Securities Raises Price Target on Sagimet Biosciences to $47 From $31, Maintains Market Outperform Rating	Jan. 23	MT
TD Cowen Initiates Sagimet Biosciences With Outperform Rating	23-08-08	MT
Goldman Sachs Initiates Sagimet Biosciences at Buy With $33 Price Target	23-08-08	MT
Piper Sandler Initiates Sagimet Biosciences With Overweight Rating, $67 Price Target	23-08-08	MT
JMP Securities Starts Sagimet Biosciences With Market Outperform Rating, $30 Price Target	23-08-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW